Risedronic acid
- Generic Name
- Risedronic acid
- Brand Names
- Actonel, Atelvia
- Drug Type
- Small Molecule
- Chemical Formula
- C7H11NO7P2
- CAS Number
- 105462-24-6
- Unique Ingredient Identifier
- KM2Z91756Z
- Background
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteoporosis, Paget’s Disease
- Associated Therapies
- -
Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
- Conditions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 248
- Registration Number
- NCT00616694
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Effect of Actonel on Periodontal Health of Postmenopausal Women
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Registration Number
- NCT00594334
- Locations
- 🇺🇸
Uhcmc, Cleveland, Ohio, United States
Bone Microarchitecture in Osteopenic Postmenopausal Women
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 13
- Registration Number
- NCT00577395
- Locations
- 🇦🇷
Research Facility, Buenos Aires, Argentina
🇺🇸Research Site, Cincinnati, Ohio, United States
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 32
- Registration Number
- NCT00577850
- Locations
- 🇺🇸
Research Facility, Gainesville, Florida, United States
🇺🇸Research Site, New Orleans, Louisiana, United States
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 370
- Registration Number
- NCT00577837
- Locations
- 🇵🇱
Research Facility, Bialystok, Poland
🇵🇱Research Site, Wroclaw, Poland
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2011-09-28
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 32
- Registration Number
- NCT00577421
- Locations
- 🇸🇪
Research Facility, Goteborg, Sweden
🇦🇺Research Site, Concord, Australia
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 181
- Registration Number
- NCT00577720
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
🇺🇸Research Facility, San Antonio, Texas, United States
Satisfaction and Compliance of Risedronate in PMO
- Conditions
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2007-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT00549965
- Locations
- 🇰🇷
Sanofi-Aventis, Daegu, Korea, Republic of
ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
- Conditions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT00544180
- Locations
- 🇮🇱
Sanofi-Aventis, Natanya, Israel
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 923
- Registration Number
- NCT00541658
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
🇧🇪Research Facility, Diepenbeek, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.